Weather

86°F2:44 PM

Health

1 read

Estudio revela confusión sobre medicamentos entre estadounidenses de mediana edad

KVIA•Wednesday, June 10, 2026 at 3:22 PM•CNN Newsource

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

Un nuevo estudio ha encontrado que casi un tercio de los estadounidenses de mediana edad enfrenta dificultades para entender las instrucciones de sus medicamentos, lo que puede resultar en errores en la dosificación y la administración. La investigación, que incluyó a 942 pacientes con una edad promedio de 52 años, destaca la necesidad de mejorar la comunicación en el sistema de salud. Muchos participantes no recordaban detalles críticos de sus diagnósticos o instrucciones de medicamentos solo 10 minutos después de recibirlos. Los expertos enfatizan la importancia de hacer preguntas durante las consultas médicas para mejorar la alfabetización en salud y asegurar un uso efectivo de los medicamentos.

Key Details: • Casi 1 de cada 3 estadounidenses de mediana edad tiene problemas con la alfabetización en salud. • El estudio incluyó a 942 pacientes con una edad promedio de 52 años. • Se recomienda a los pacientes hacer preguntas abiertas a médicos y farmacéuticos sobre sus medicamentos. • Llevar una lista de medicamentos puede ayudar a recordar qué se está tomando y por qué.

salud investigacion medicamentos alfabetizacion sistema-salud

People & Organizations

Abigail VogeleyMichael WolfJan CarneyStefanie FerreriFacultad de Medicina FeinbergUniversidad NorthwesternColegio Americano de MédicosFacultad de Medicina Robert LarnerFacultad de Farmacia Eshelman

Related Articles

New Research Links Hearing Loss to Increased Alzheimer's Risk

As the population ages, the number of individuals diagnosed with Alzheimer's disease is projected to double by 2060, highlighting the urgent need for early detection and intervention. Recent studies suggest that hearing loss may be a significant warning sign of cognitive decline, prompting researchers to explore its implications for Alzheimer's risk. Understanding these connections could lead to better preventative strategies for those at risk. This research is crucial for healthcare providers and families in El Paso and beyond, as it emphasizes the importance of addressing hearing health as part of cognitive wellness.

El Paso Matters•Jun 21

El Paso Sees Decline in Accidental Deaths and Drug Overdose Trends in 2025

The latest report from the El Paso County Office of the Medical Examiner reveals a significant 32% decrease in accidental deaths from 2023 to 2025, primarily due to reductions in motor vehicle accidents and drug overdoses. Notably, cocaine-related deaths have surged, surpassing fentanyl for the first time since 2019, with 60 deaths attributed to cocaine last year. Cardiovascular disease remains the leading cause of sudden natural deaths, with high diabetes rates contributing to this trend. The report highlights the ongoing public health challenges in El Paso, including mental health issues among youth, as suicide rates remain stable but concerning, particularly among boys aged 11-18. Residents are encouraged to utilize local mental health resources.

Medicare Initiates Pilot Program for Expanded Access to GLP-1 Medications

Medicare has announced a pilot program aimed at enhancing access to GLP-1 medications, which are commonly used for diabetes and weight management. This program will be operational from July 1, 2026, through December 31, 2027. The initiative is significant as it seeks to address the growing need for effective treatments in managing chronic conditions, potentially benefiting numerous patients. Stakeholders in the healthcare community should prepare for the changes and consider how this may affect patient care and medication availability.

Medicare's New Pilot Program to Enhance Access to GLP-1 Medications

Medicare has announced a pilot program aimed at increasing access to GLP-1 medications, which are commonly used for diabetes and weight management. This demonstration will commence on July 1, 2026, and continue until December 31, 2027. The initiative is significant as it addresses the growing demand for these treatments, potentially benefiting many patients who struggle to afford them. Residents should be aware of this upcoming program, as it could impact their healthcare options and costs related to GLP-1 drugs.